Praxis Precision Medicines, Inc. PRAX Shares (Diluted)
Shares (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Praxis Precision Medicines, Inc. in its filing.
Tagged under the XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding.
The official record: Praxis Precision Medicines, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Praxis Precision Medicines, Inc.'s shares (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Praxis Precision Medicines, Inc.'s shares (diluted)?
- Praxis Precision Medicines, Inc. (PRAX) reported shares (diluted) of 28.9M in Q1 2026.
- How has Praxis Precision Medicines, Inc.'s shares (diluted) changed year-over-year?
- Praxis Precision Medicines, Inc.'s shares (diluted) increased by 37.2% year-over-year, from 21.1M to 28.9M.
- What is the long-term trend for Praxis Precision Medicines, Inc.'s shares (diluted)?
- Over 4 years (2021 to 2025), Praxis Precision Medicines, Inc.'s shares (diluted) has grown at a -15.1% compound annual growth rate (CAGR), from 167.2M to 87M.
- What does shares (diluted) mean?
- The total number of shares that would exist if all convertible securities and stock options were converted into common stock.
- How do you interpret shares (diluted)?
- An increase in diluted shares typically indicates potential dilution for existing shareholders due to the issuance of new shares, stock-based compensation, or the conversion of debt instruments. A decrease generally suggests share buybacks or a reduction in outstanding dilutive instruments.
- How does shares (diluted) compare across companies?
- Biopharmaceutical companies often show increasing diluted share counts over time due to the frequent use of equity-based compensation to attract talent and the issuance of shares to fund clinical development programs.